HOME > BUSINESS > Lupin gets approval for new indigestion tablets in India

Lupin gets approval for new indigestion tablets in India

indigestionLupin Ltd announced today that it has received approval to launch Acotiamide 100 mg indigestion tablets in India from the Central Drugs Standard Control Organization.

Acotiamide is a drug to be introduced into the Indian Pharmaceutical Market which
could benefit millions of patients suffering from Dyspepsia or Indigestion, most common stomach complaints encountered in clinical practice.

Acotiamide enhances gastric accommodation and gastric emptying, the two factors which have been implicated in the cause of functional dyspepsia.

“I am sure that the approval of Acotiamide would go a long way in addressing an otherwise common but unmet medical need for a safe and effective drug for the management of dyspepsia” said, Naresh Gupta, President, Lupin Ltd.

The current market for plain Gastrointestinal prokinetics drugs is estimated to be around ₹2,640 Cr growing at 14%.

Lupin is transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally.

Follow ULTRA.news
Panacea Biotech, Serum Institute in polio vaccine tie-up Panacea Biotec said it signed two long-term agreements with the world's largest vaccine manufacturer, Serum Institute of India Pvt. Ltd, for manufacturing polio vaccines with a potential market size of $1.25 bln per year. The vaccine will also protect against six other diseas...
Ipca Laboratories acquires US pharma manufacturer for $9.65 mln Ipca Laboratories Ltd said it is has acquired US-based drug manufacturer Pisgah Labs Inc. for US$ 9.65 millions free of debt. The acquisition is aimed at establishing the company's foothold in the US market in the field of contract research and small-volume manufacturing of a...
OrbiMed Asia invests $7.5 mln more in Vivimed Labs unit Vivimed Labs said it will receive $7.5mn investment from OrbiMed Asia into its API business as a follow on to the $42.5 mn invested in September 2017. At the time, Vivimed has said that the proceeds will be utilised for debt reduction at the parent entity level as well as for...
Lupin gets USFDA nod for scalp solution Pharma Major Lupin announced that it has received final approval from the US Food & Drug Administration to market a generic version of Dovonex Scalp Solution from Leo Pharmaceutical Products Ltd. Calcipotriene Topical Solution is indicated for the topical treatment of chroni...
Sun Pharma’s eye drug application accepted by USFDA Sun Pharmaceutical Industries Ltd said the US FDA has accepted a New Drug Application (NDA) for its OTX-101 dry eye drug. The application will now be processed for approval. Dry eye is a condition in which the eye does not produce tears properly, or when the tears are not of t...
Suven gets neuro drug patents in India, Canada Suven Life Sciences Ltd said it has been granted one patent each in Canada and India for drugs for treating Neurodegenerative diseases. The Canadian patent 2932428 is valid through 2034 and the Indian patent 289123 is valid through 2028. The chemical entities are consider...
Lupin gets US approval for generic version of Bayer’s oral contraceptive Pharma Major Lupin said it got the approval of the US Food and Drug Administration to launch a generic version of Bayer's oral contraceptive Safyral. The branded version has annual sales of around $23 mln in the US. Lupin's product will be called Tydemy. The combination...
Glenmark reports successful trial for nasal spray, to file NDA soon Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that its nasal spray Ryaltris met safety and efficacy goals in a Phase 3 clinical study in treating perennial allergic rhinitis. With the positive results, the company said it plans to submit an applica...
Neuland Laboratories acquires Hyderabad factory from Arch Pharma Pharma manufacturer Neuland Laboratories said it acquired a manufacturing plant located near Hyderabad from Arch Pharma Labs Limited. The facility is spread across 12 acres and has a capacity of about 197 KL, the company said. The plant was inspected by the USFDA in 2015, ...
DENGUE DEATH: Haryana govt probe finds Fortis Hospital guilty An official inquiry by the Haryana government has found the Gurgaon Fortis hospital guilty of overcharging and several other violations of law, media outlets reported. Quoting the official copy of the report, Mirror Now said that the inquiry committee found the hospital guilty...
Eris Lifesciences completes acquisition of Strides Shasun India generics ops Pharma company Eris LifeSciences said it has completed its purchase of the India branded generics of Strides Shasun for Rs 500 cr in cash. "We now wish to confirm that the transaction ahs achieved closure," said Eris Lifesciences. Last month, Strides Shasun said it was sel...
Crucial win for Biocon as FDA approves cancer biosimilar trastuzumab Biocon and its partner Mylan scored a key victory on Friday as the US Food & Drug Administration approved its cancer-treating biosimilar trastuzumab. "Mylan anticipates potentially being the first company to offer a biosimilar to Herceptin, as a result of Mylan's ability to s...
Boosted by Jio’s success, Mukesh Ambani unveils his future plans Mukesh Ambani, India's richest man, said telecom was the first of his big bet, and he will now use his resources to solve problems in three other difficult areas -- agriculture, education and healthcare. Speaking at the HT Leadership Summit, Ambani said his primary motivation...
EU accepts Biocon, Mylan’s application for cancer biosimilar pegfilgrastim Indian pharma company Biocon and its partner Mylan said EU authorities have accepted for review their applications for approving cancer treating biosimilars trastuzumab and pegfilgrastim submitted after completing corrective actions. The applications were resubmitted last mo...
Dr Reddy’s says EU approves production at Duvvada plant in Andhra Pharma major Dr Reddy's Laboratories said European Union authorities have again allowed it to produce drugs for sale in the EU region at its Duvvada factory in Andhra Pradesh. In its inspection conducted in September, the Regulatory Authority of Germany (Regierun von Oberbayer...
Panacea Biotec gets US nod for generic version of cancer drug Abraxane Panacea Biotec said it got the regulatory nod in the US for launching a generic version of big-selling cancer drug Abraxane. The drug will be sold with the help of Canadian pharmaceutical distributor Apotex. The annual sale of Abraxane worldwide is approximately US$973.4 m...
Dr Reddy’s gets served with class action lawsuit Pharma major Dr Reddy's Laboratories said it has been served with a class action lawsuit, originally announced in August, related to public disclosures made about regulatory action against the company. "Further to our intimation dated August 28, 2017 with regard to US Securit...
Strides Shasun says Eris deal to help reprioritize business, lower debt Pharma major Strides Shasun said it agreed to sell its India branded generics business to Eris LifeSciences Limited for Rs 500 cr in cash. "This transaction is the outcome of the company's portfolio reprioritization, to focus more sharply on larger regulated markets," it said...
Zydus gets nod for anti-inflammation drug in the US Pharma major Zydus Cadila said it received final approval from the USFDA to market an anti-inflammatory injection Ethacrynate Sodium in the US. The drug is used to decrease the Swelling (edema) caused by various disease conditions such as liver disease, kidney disease, conges...
Cipla launches ashtha inhaler therapy in the US Pharma giant Cipla Ltd said it received final approval for launching a generic version of Astrazeneca’s Pulmicort inhalation suspension for pediatric asthma in the US. The product is available for shipping immediately, Cipla said. Pulmicort Respules and generic equivalent...